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Abstract 
Citrullination is the post-translational conversion of an arginine residue within a protein 
to the non-coded amino acid citrulline1.  This modification leads to the loss of a positive 
charge and reduction in hydrogen bonding ability. It is carried out by a small family of 
tissue-specific vertebrate enzymes called peptidylarginine deiminases (PADIs)2 and is 
associated with the development of diverse pathological states such as autoimmunity, 
cancer, neurodegenerative disorders, prion diseases and thrombosis2,3. Nonetheless, the 
physiological functions of citrullination remain ill-defined, though citrullination of core 
histones has been linked to transcriptional regulation and the DNA damage response 4-8. 
PADI4 (or PAD4/PADV), the only PADI with a nuclear localization signal9, was previously 
shown to act in myeloid cells where it mediates profound chromatin decondensation 
during the innate immune response to infection10. Here we show that the expression and 
enzymatic activity of PADI4 are also induced under conditions of ground state 
pluripotency and during reprogramming. PADI4 is part of the pluripotency transcriptional 
network, binding to regulatory elements of key stem cell genes and activating their 
expression. Its inhibition lowers the percentage of pluripotent cells in the early mouse 
embryo and significantly reduces reprogramming efficiency. Using an unbiased 
proteomic approach we identify linker histone H1 variants, which are involved in the 
generation of compact chromatin11, as novel PADI4 substrates. Citrullination of a single 
arginine residue within the DNA binding site of H1 results in its displacement from 
chromatin and global chromatin decondensation. Together, these results uncover a role 
for citrullination in the regulation of pluripotency and provide new mechanistic insights 
into how citrullination regulates chromatin compaction.  
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Pluripotent cells have the capacity to self-renew and differentiate into all somatic and germ cell 
lineages and, hence, possess immense therapeutic potential for a multitude of medical 
conditions. Their generation by reprogramming of differentiated somatic cells has been 
achieved by nuclear transfer, cell fusion and transduction of transcription factors, such as Oct4, 
Sox2, Klf4 and c-Myc12. Pluripotent cells have a distinctly open chromatin structure that is 
essential for unrestricted developmental potential13,14 and reprogramming involves an almost 
complete epigenetic resetting of somatic cells13. The ability of PADI4-mediated histone 
citrullination to induce chromatin decondensation in neutrophils10 prompted us to ask whether it 
can play a role in pluripotency, where chromatin decondensation is also necessary. To 
investigate this we first assessed the expression of Padi4 in the embryonic stem cell line ES 
Oct4-GIP (ES), the neural stem cell line NSO4G (NS) and in induced pluripotent stem (iPS) 
cells derived NSO4G (see Methods). Padi4 is expressed in pluripotent ES and iPS but not 
multipotent NS cells (Fig.1a). Culture of ES cells in 2i/LIF medium establishes a ground state of 
pluripotency15. This leads to the down-regulation of lineage specific markers and the up-
regulation of pluripotency factors, as well as rapid induction of Padi4 (Fig. 1b). The pattern of 
Padi4 expression follows closely that of Nanog, an essential transcription factor for the transition 
to ground state pluripotency16(Fig 1a,b). While other PADIs are expressed in pluripotent cells, 
PADI4 is the only one whose expression clearly associates with naïve pluripotency (Extended 
Data Fig. 1a,b). Citrullination of histone H3 (H3Cit), a modification shown previously to be 
carried out specifically by PADI417, is detectable in ES and iPS cells (Extended Data Fig. 1c), 
indicating that PADI4 is also enzymatically active. H3 and global citrullination are undetectable 
in NS cells (Extended Data Fig. 1c,d).  
 
To determine the kinetics of PADI4 activation during the establishment of pluripotency, we 
examined RNA and protein samples collected daily during the course of reprogramming of 
NSO4G into iPS cells16. Padi4 is rapidly induced in NS cells after transduction of reprogramming 
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factors but only becomes active to citrullinate H3 after introduction of 2i/LIF, closely following the 
onset of Nanog expression (Fig. 1c). These observations strongly suggested that PADI4 activity 
is associated with ground state pluripotency and prompted us to examine whether Padi4 is part 
of the pluripotency transcriptional network.  
 
First, we asked whether the reprogramming factors regulate Padi4 expression, utilizing the 
ZHBTc4.1 and 2TS22C cell lines where Oct4 and Sox2, respectively, can be deleted acutely in 
response to doxycycline treatment (see Methods). Deletion of Oct4, but not Sox2, led to a 
decrease in Padi4 mRNA levels (Extended Data Fig. 1e). Furthermore, while Oct4 and Klf4 
occupy the Padi4 promoter in ES, but not NS cells, Sox2 is bound in both cell types (Extended 
Data Fig. 1f). To understand the effects of PADI4 on transcriptional regulation in pluripotent 
cells, we analyzed the transcriptome of ES cells upon PADI4 over-expression and inhibition. 
Several key pluripotency genes are up-regulated in response to PADI4 over-expression (Fig. 
1d, Extended Data Figure 2a and Supplementary Table 2), including Klf2, Tcl1, Tcfap2c, and 
Kit. Tcl1 was previously identified as the only regulator of self-renewal up-regulated in ground 
state pluripotency15 and over-expression of Tcl1 or Tcfap2c positively influence this process18. 
Gene Ontology (GO) analysis of this dataset indicates an enrichment of genes involved in stem 
cell development and maintenance (Fig. 1e). In addition, knockdown of Padi4 in mES cells 
leads to decreased expression of Tcl1 and Nanog, which is rescued by exogenous expression 
of RNAi-resistant human PADI4 (Fig. 1f, Extended Data Fig. 2b,c). These genes are under the 
control of PADI4 enzymatic activity since treatment with the chemical inhibitor Cl-amidine, which 
disrupts citrullination by PADI419, down-regulates their expression (Fig. 1g). Chromatin 
immunoprecipitation (ChIP) analysis indicated that H3Cit is present on regulatory regions of 
Tcl1 and Nanog in ES and iPS cells, but not NS cells (Fig. 1h and Extended Data Fig. 3a). 
Accordingly, exogenously expressed human PADI4 localizes to and is enzymatically active on 
these regions, as well as regulatory regions of Klf2 and Kit in ES cells (Extended Data Fig. 
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3b,c). In contrast to PADI4 over-expression, treatment of ES cells with Cl-amidine led to up-
regulation of differentiation markers such as Prickle1, EphA1 and Wnt8a and down-regulation of 
pluripotency markers such as Klf5 (Extended Data Fig. 4a,b, and Supplementary Table 3), in 
addition to Nanog and Tcl1 (Fig. 1g). GO analysis of this dataset indicated enrichment in genes 
involved in cell differentiation (Extended Data Fig. 4c). Pou5f1 (Oct4), Klf4, Sox2 and c-Myc, 
were not affected by PADI4 modulation (Extended Data Fig. 2a and  Supplementary Tables 2 
and 3). Cumulatively, the above results place PADI4 within the pluripotency transcriptional 
network, suggesting that it acts downstream of some of the cardinal reprogramming factors to 
regulate a specific subset of pluripotency genes.  
 
Prompted by the above observations, we investigated whether PADI4 is necessary for 
pluripotency, as assessed during reprogramming (Extended Data Fig. 5a) and in the early 
stages of embryo development. NSO4G cells express a GFP reporter under the control of the 
Oct4 regulatory sequences, which is activated upon acquisition of pluripotency16, allowing us to 
trace reprogrammed cells. Knock-down of Padi4 in NSO4G-derived pre-iPS cells impaired the 
ability of the cells to establish H3Cit upon switch to 2i/LIF medium and led to a clear reduction in 
reprogramming (Fig. 2a,b, Extended Data Fig. 5b-e and Extended Data time-lapse video). 
Consistent with this, levels of Tcl1 and Nanog were not elevated upon reprogramming to the 
same extent as in control cells (Fig. 2b and Extended Data Fig. 5f). Cl-amidine treatment led to 
a dramatic reduction of reprogramming efficiency and H3Cit (Fig. 2c and Extended Data Fig. 5g-
i), suggesting that the catalytic activity of PADI4 is important for the induction of pluripotency. 
 
Padi4 expression and H3Cit are detected in the early embryo20,21 and Padi4-null mice are born 
in lower numbers than would be expected by Mendelian inheritance22, suggesting that PADI4 
loss affects embryonic development. To assess the role of PADI4 in early development, we 
cultured mouse embryos in Cl-amidine-containing medium from the 2-cell stage and throughout 
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pre-implantation development (see Methods and Extended Data Fig. 6a-c). Using 200µM Cl-
amidine resulted in a complete developmental arrest of the embryos at the 8-cell stage 
(Extended Data Fig. 6a). We therefore used the maximum dose of Cl-amidine that reduced 
H3Cit (Extended Data Fig. S6b,c) but did not induce arrest (10µM). This led to a reduced 
percentage of pluripotent Nanog-positive epiblast cells and an increased percentage of 
differentiated trophectoderm cells at the blastocyst stage (Fig. 2d,e and Extended Data Fig. 
6d,e). Time-course analyses of the cleavage patterns and cell fate decisions in early embryos 
showed that Cl-amidine increased the number of symmetric cell divisions at the expense of 
asymmetric divisions at the 8 to 16- and 16 to 32-cell transitions (Fig. 2f,g). This resulted in 16-
cell stage embryos with fewer inner cells (destined for pluripotency) and greater numbers of 
outer cells (destined for differentiation into trophectoderm, reviewed in 23) (Extended Data Fig. 
6f). Treatment with another PADI4 inhibitor, TDFA24, but not the HDAC inhibitor TSA, had 
similar effects (Extended Data Fig. 7, 8). These results indicate that PADI4 activity also 
promotes the maintenance of pluripotent cells in the early mouse embryo. 
 
To elucidate the molecular mechanisms by which PADI4 regulates pluripotency, we aimed to 
identify PADI4 substrates in the chromatin fraction of mES cells using Stable Isotope Labeling of 
Amino acids in Cell culture (SILAC) (Fig. 3a and Extended Data Fig. 9a,b). Among the identified 
PADI4 substrates were Atrx, Dnmt3b, Trim28 and variants of linker histone H1 (Fig. 3b-e, 
Extended Data Fig. S9c-f, S10 and Supplementary Table 4), all of which can impact 
pluripotency. Histone H1 stabilizes the nucleosome and facilitates chromatin condensation, a 
state that is less permissive to processes that require access to the DNA, such as 
transcription11. The identified citrullinated H1 peptides correspond to, and are common between, 
variants H1.2, H1.3 and H1.4 (Fig. 3d,e), while an additional peptide corresponds to the same 
residue in H1.5 (Extended Data Fig. 10a,b). In ES cells, H1.2, H1.3 and H1.4 are required for 
chromatin compaction25, while their depletion leads to increased expression of pluripotency 
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genes such as Nanog and stalls them in a self-renewal state with impaired differentiation 
capability26. Notably, H1 is more loosely bound to chromatin in ES cells than in differentiated 
cells14 and its genomic localization in cancer cells was shown to anti-correlate with that of 
PADI47. 
 
Mass spectrometric analysis accounted for all arginine residues within H1 but indicated that 
Arg54 (H1R54) is the only site citrullinated by PADI4 (Fig. 3e and Extended Data Fig. 9c). 
Indeed, we found that while H1.2 is citrullinated in ES cells (already by endogenous PADI4, and 
significantly increased upon PADI4 over-expression), it is refractory to modification when Arg54 
is mutated (Fig. 3f). Similar results were obtained in in vitro citrullination assays (Extended Data 
Fig. 11a). H1R54 lies within the globular domain of H1 (Extended Data Fig. 11b), which is highly 
conserved among the linker histone family and is necessary for interaction with nucleosomal 
DNA27,28. To test whether H1R54 is necessary for binding of H1 to nucleosomes, we mutated 
and assessed it in nucleosome-binding assays. Figure 3g shows that an R54A mutant, which 
mimics the charge change that accompanies citrullination, is impaired for nucleosome binding. 
An R54K mutant, which retains the positive charge, is impaired to a lesser extend (Fig. 3g) 
suggesting that H1R54 is important for electrostatic interactions between H1.2 and the 
nucleosome.  
 
The above results open up the possibility that PADI4 may affect chromatin compaction in 
pluripotent cells. To test this hypothesis, we first assessed whether citrullination by ectopic 
PADI4 can lead to decondensation of differentiated cell chromatin. Recombinant PADI4 was 
added to permeabilized and stabilized differentiated C2C12 mouse myoblast nuclei (Fig. 4a). 
This protocol ensures stabilization of the nuclear component while allowing the free diffusion of 
non-chromatin bound nuclear proteins into the extra-nuclear fraction, and their collection by 
washing. Incubation with active PADI4 (Extended Data Fig. 12a,b), leads to the eviction of H1 
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from the chromatin and its diffusion out of the permeabilized nucleus (Fig. 4b). The evicted H1 is 
citrullinated on R54, as determined by mass spectrometry (Extended Data Figure 12c,d). 
Consistent with this, PADI4-treated cells showed evidence of decondensed chromatin, as 
determined by nuclear swelling, diffuse DAPI staining and increased sensitivity to micrococcal 
nuclease (Fig. 4c,d and Extended Data Figure 12e). Similar results were observed when PADI4 
was over-expressed in C2C12 cells (Fig. 4e) or NS cells (data not shown). To monitor if PADI4 
can affect H1 binding on pluripotent cell chromatin, we performed ChIP-qPCR analyses of H1.2 
on the regulatory regions of Tcl1 and Nanog and found that it is stabilized upon Padi4 
knockdown (Fig. 4f). The ability of PADI4 to disrupt the binding of H1 to nucleosomal DNA 
provides a novel mechanistic example of how citrullination regulates protein function and 
chromatin condensation. 
 
The work described above identifies citrullination of chromatin components by PADI4 as a 
feature of pluripotency (Fig. 4g), in addition to its previously described role in the myeloid 
lineage. One of the reasons for the restricted expression pattern of PADI4 may be the 
requirement for an open chromatin state in these cell types. The selective expression 
characteristics and the inducible nature of the catalytic activity of PADI4, suggest that it is under 
tight spatial and temporal regulation, giving it a unique status among chromatin modifying 
enzymes. As such, inappropriate PADI4 activity may have deleterious consequences, which 
may explain its activation in cancers of varying origin during progression to malignancy29. 
Indeed, citrullination is a common feature of several unrelated diseases, suggesting that strict 
regulation is likely to be a requirement for the physiological function of all PADIs. During review 
of this manuscript, Coonrod and colleagues suggested that PADI2, thought to be mainly 
cytoplasmic, can also citrullinate histones and lead to transcriptional activation30. This opens the 
intriguing possibility that other PADIs may mediate nuclear events in specific contexts, including 
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in pluripotent cells. Further research into the function and targets of PADIs is likely to shed light 
into the etiology of several pathologies. 
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Supplemental Information 
Complete experimental methods and references in Methods file. 
Extended Data figure legends in “Extended Data figure legends” file. 
Primer sequences in Supplementary Table S1. 
Complete microarray data for PADI4 over-expression in ES cells in Supplementary Table S2. 
Complete microarray data for PADI4 inhibition in ES cells in Supplementary Table S3. 
Complete Mass Spec dataset in Supplementary Table S4. 
Time-lapse video of reprogramming experiments in Supplementary video file. 
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Figure Legends 
 
Figure 1: PADI4 expression and activity are features of pluripotent cells 
 
(a,b) qRT-PCR for Padi4 and Nanog expression in ES, NS and iPS cells (a), and in ES cells 
upon culture in 2i/LIF for one passage (b). Pou5f1, Olig2 and Pax6 are presented as controls. 
Expression normalized to Ubiquitin (UbC). Error bars: standard error of the mean of three 
biological replicates.  
 
(c) qRT-PCR for Padi4 and Nanog expression and H3Cit immunoblot during the course of 
reprogramming (see also Extended Data Fig. 5a). Loading control: total histone H3. 
Representative of four experiments. 
 
(d) Heat map of the genes regulated upon hPADI4 over-expression in mES cells, as determined 
by microarray analysis. Displayed values are normalized log intensities, minus the mean 
expression of the gene across the four samples. Hierarchical clustering based on correlation. 
 
(e) Gene Ontology for Biological Process (GOBP) analysis of the above microarray dataset. P-
value is corrected for multiple testing using Benjamini and Hochberg False Discovery Rate 
(FDR). 
 
(f,g) qRT-PCR for Tcl1 and Nanog expression in mES cells after transient knock-down with 
Padi4 or control (Ctrl) shRNAs, and over-expression of human PADI4 or control vector (pPB 
CTRL) (f), and after treatment with 200µM Cl-amidine (g). Expression normalized to UbC. Error 
bars: standard error of the mean of three biological replicates. 
 
(h) ChIP-qPCR for H3Cit on regulatory regions of Tcl1 and Nanog in mES, NS and iPS cells. 
Error bars: standard deviation of three technical qPCR replicates. Representative of three 
experiments. 
 
Asterisks denote difference with ES cells (a) or media (b), Control (f, g) and between samples 
(f); - not significant, * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001,  by ANOVA (a,f) or t-test 
(b,g). 
 
 
Figure 2: Citrullination and PADI4 regulate pluripotency during reprogramming and early 
embryo development 
(a) Flow cytometry analysis and phase contrast/fluorescence images for the assessment of 
Oct4-GFP reporter expression after reprogramming of pre-iPS cells stably expressing Padi4 and 
Ctrl shRNAs. Representative of four independent experiments. Time-lapse video in 
supplementary data online. 
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(b) qRT-PCR for expression of Tcl1, Nanog and Padi4 at the end of the above reprogramming 
assay. Error bars: standard error of the mean of triplicate samples. 
 
(c) Flow cytometry analysis and phase contrast/fluorescence images for the assessment of 
Oct4-GFP reporter expression after reprogramming assay of pre-iPS cells treated with 200µM 
Cl-amidine. Representative of three independent experiments. 
 
(d) E4.5 blastocysts from 2-cell stage embryos treated with 10µM Cl-amidine. SOX17 (primitive 
endoderm marker, red), Cdx2 (trophectoderm marker, green), Nanog (epiblast marker, white) 
and HOECHST 33342 (blue). 
 
(e) Distribution of inner cell mass versus trophectoderm cells in E3.5 blastocyst treated as 
above.  
 
(f,g) Time-lapse analysis of embryos in 10µM Cl-amidine from 2-cell stage. Number of 
symmetric versus asymmetric divisions at the 8 to 16-cell transition (f) and type of divisions at 
the 16 to 32-cell transition (g). Error bars: standard error of the mean.  
 
Statistical significance was determined by unpaired t-test (b), or Mann Whitney test upon non-
normal distribution (e-g). Asterisks denote difference with Control; - not significant, * P≤0.05, ** 
P≤0.01, *** P≤0.001, **** P≤0.0001. 
 
 
Figure 3: PADI4 citrullinates Arg54 on linker histone H1 and affects its binding to 
nucleosomal DNA 
 
(a) Experimental strategy for screening for PADI4 citrullination substrates in the chromatin 
fraction of ES cells.  
 
(b) Scatter plot representing the overall fold change for all identified citrullination sites. Red 
diamonds: PADI4-regulated citrullinations.  
 
(c) Table representing the 40 most highly regulated PADI4 substrates, their individual 
citrullination sites and the log2 SILAC ratio. Complete dataset in Supplementary Table 4. 
 
(d) Quantification of citrullination site R54 on H1.2 through differential regulation of the triply 
charged peptide ERSGVSLAALKK. 
 
(e) Fragmentation spectra of the triply charged and heavy SILAC labeled LysC peptide 
ERSGVSLAALKK surrounding Arginine 54 of H1.2. The y and b series indicate fragments at 
amide bonds of the peptide. 
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(f) Citrullination immunoblot of wild-type and R54A mutant GFP-tagged H1.2 expressed and 
pulled-down from ES cells expressing PADI4 or control vector (Mock). Control for the efficiency 
of the pull-down: GFP. 
 
(g) Nucleosome pull-down assay using wild-type and R54-mutant H1.2. WB: Western Blot. 
 
Figure 4: PADI4 evicts histone H1 from chromatin and affects chromatin condensation 
 
(a) Schematic representation of treatment of C2C12 myoblast nuclei with recombinant PADI4.  
 
(b) Immunoblot analysis of the wash fraction after the above treatment, for histone H1.2.  
 
(c,d) Quantification of nuclear volume (c) and representative DAPI fluorescence (d) upon 
treatment of permeabilized C2C12 nuclei with recombinant PADI4. Error bars: standard error of 
the mean. Statistical significance determined by unpaired student t-test. 
 
(e) Micrococcal nuclease digestion of C2C12 cells overexpressing an empty vector (Mock) or 
hPADI4. 
 
(f) ChIP-qPCR for H1.2 on the regulatory regions of Tcl1 and Nanog in mES cells stably 
expressing Padi4 or Ctrl shRNA. Error bars: standard error of the mean of three technical qPCR 
replicates. Representative of two experiments.  
 
(g) Proposed model for the role of PADI4 in the regulation of pluripotency.  
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Lineage commitment in E4.5 blastocysts developed in the presence of Cl-amidine
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Data from 3 replicates and 50 E4.5 blastocysts (n = 24-26 per group)
CT
RL
Cl-
am
idi
ne
0
50
100
Di
st
rib
ut
io
n 
of
 ce
lls
 in
 16
 ce
ll  
em
br
yo
 (%
)
Inner cells
Outer Cells
*
*
8 to 16
cell transition
f
Phase
E4.5 Blastocysts
Sox17 CDX2 Hoechst Merge
 C
trl
Cl
-a
m
id
in
e
a b
c
 C
trl
TD
FA
 Phase Nanog Sox17 Cdx2 Hoechst
E4.5 Blastocysts
merge
 C
trl
TD
FA
H3 Cit HoechstPhase
4 cell stage
Kouzarides_Extended Data Figure 7
Lineage commitment in E4.5 blastocysts developed in the presence of TDFA
Percentage of EPI cells 
(mean±SE)
Percentage of TE cells 
(mean±SE)
Percentage of PE cells 
(mean±SE)
Control 12,60±0,79 77,02±0,94 10,38±0,60
TDFA 10,43±0,62* 78,70±0,68 10,87±0,62
Data from 3 replicates and 60 E4.5 embryos (n=28-32 per group)
* Asterisks indicate difference within the same column (Mann Whitney test, P<0.05)
EPI: epiblast, TE: trophoectoderm , PE: primitive endoderm
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Lineage commitment in E4.5 blastocysts developed in the presence of TSA
Percentage of EPI cells 
(mean±SE)
Percentage of TE cells 
(mean±SE)
Percentage of PE cells 
(mean±SE)
Control 10,06±0,67 77,29±0,86 12,64±0,61
TSA 10,71±0,80 79,34±0,91 9,95±0,60*
Data from 2 replicates and 32 E4.5 embryos (n=15-17 per group)
* Asterisks indicate difference within the same column (unpaired T-test, P<0.05)
EPI: epiblast, TE: trophoectoderm , PE: primitive endoderm
db
-4 0 4 8-8
log2 ratios (Heavy/Light)
Pe
pt
id
e 
ab
un
da
nc
e
AASGEAKPQA
Cit
Identified peptide sequence 
by mass spectrometry
Sequence coverage of H1f2
 
 
        10         20         30         40         50         60  
MSEAAPAAPA AAPPAEKAPA KKKAAKKPAG VRRKASGPPV SELITKAVAA SKERSGVSLA  
 
        70         80         90        100        110 120  
ALKKALAAAG YDVEKNNSRI KLGLKSLVSK GILVQTKGTG ASGSFKLNKK   
 
       130        140        150        160        170 180  
KKAGAAKAKK PAGAAKKPKK ATGAATPKKA AKKTPKKAKK PAAAAVTKKV AKSPKKAKVT  
 
       190        200        210  
KPKKVKSASK AVKPKAAKPK VAKAKKVAAK KK  
e
c
Kouzarides_Extended Data Figure 9
f
a
0
10000
20000
30000
40000
50000
60000
70000
-20 -15 -10 -5 0 5 10 15 20
Co
un
t
Peptide mass deviation bins [ppm]
Measured mass deviations on HCD fragment ions
(based upon >490.000 b- and y- ions)
100 200 300 400 500 600 700 800 900 1000 1100 1200
m/z
0
50
100
Re
la
tiv
e A
bu
nd
an
ce
E R S G V S L A A L K K
b
y
y1
y2
y3 y4 y5 y6
y7
b3 b4
b11
b10
b9
b8
b7b6
b5
b2
MH
2+
a10
a9
b-ion Theo. Mass Mass PPM 
b2 286.1515 286.1502 4.54 
b3 373.1836 373.1808 7.50 
b4 430.2050 430.2068 4.18 
b5 529.2734 529.2703 5.86 
b6 616.3055 616.3045 1.62 
b7 729.3895 729.3867 3.84 
b8 800.4266 800.4236 3.75 
b9 871.4638 871.4616 2.52 
b10 984.5478 984.5458 2.03 
b11 1118.6629 1118.6654 2.23 
y-ion Theo. Mass Mass  
y1 153.1335 153.1326 5.88 
y2 287.2486 287.2474 4.18 
y3 400.3326 400.3318 2.00 
y4 471.3698 471.3679 4.03 
y5 542.4069 542.4033 6.64 
y6 655.4909 655.4884 3.81 
y7 742.5230 742.5139 12.26 
b-ion Theo. Mass Mass PPM 
b2 287.1355 287.1343 4.18 
b3 374.1676 374.1649 7.22 
b4 431.1890 431.1849 9.51 
y-ion Theo. Mass Mass PPM 
y1 153.1335 153.1325 6.53 
y2 287.2486 287.2474 4.18 
y3 400.3326 400.3315 2.75 
y4 471.3698 471.3683 3.18 
y5 542.4069 542.4055 2.58 
y6 655.4909 655.4880 4.42 
y7 742.5230 742.5204 3.50 
y8 841.5914 841.5886 3.33 
y9 898.6128 898.6099 3.23 
y10 985.6449 985.6422 2.74 
ab
Kouzarides_Extended Data Figure 10
564.0 565.0 566.0 567.0 568.0 569.0
m/z
0
50
100
Heavy SILAC peak - ERGGVSLPALK
Light SILAC peak - ERGGVSLPALK
Theoretical peptide mass: 1132.6548
Measured peptide mass: 1132.6540
Mass deviation:   <1.0 ppm
Cit
Cit
Re
la
tiv
e 
ab
un
da
nc
e
100 200 300 400 500 600 700 800 900 1000 1100
m/z
0
50
100
E R G G V S L P A L K
b
y
Cit
y1
y2
y3
y4
y5
y6
y7 y8
y9
b2
b3
Re
la
tiv
e 
ab
un
da
nc
e
a b
Kouzarides_Extended Data Figure 11
WT R54A R54K
Ca2+ + + +- --
ModCit
H1.2 Histone H1.2
DNA binding site H15
1 212115974134
a b
Merge
DNA
H3Cit
PADI4            -                  +  
PADI4    -       +  
Pellet
H3Cit
H3
c
Kouzarides_Extended Data Figure 12
M 60301510864210
Ctrl
M 60301510864210
PADI4
Time
 (mins)
b-ion Theo. Mass Mass PPM 
b2 287.1355 287.1351 1.39 
b3 374.1676 374.1667 2.41 
b4 431.1890 431.1902 2.78 
y-ion Theo. Mass Mass PPM 
y1 147.1134 147.1128 4.08 
y2 260.1974 260.1969 1.92 
y3 331.2345 331.2339 1.81 
y4 402.2716 402.2711 1.24 
y5 515.3557 515.3554 0.58 
y6 602.3877 602.3871 1.00 
y7 701.4562 701.4558 0.57 
y8 758.4776 758.4770 0.79 
y9 845.5096 845.5089 0.83 
d
100 200 300 400 500 600 700 800 900 1000 1100
m/z
0
50
100
R
el
at
iv
e 
A
bu
nd
an
ce
E R S G V S L A A L K 
b
y
Cit
y1
y2
y3
y4 y5
y6
y7
y8
y9
MH
2+
b2
b3
b4
e
Kouzarides_Supplementary Figure Legends 
	   1	  
Extended Data Figure Legends  
 
 
Extended Data Figure 1: 
 
(a) Transcript levels for Padi1, Padi2 and Padi3 in ES, NS and iPS cells, as 
assessed by qRT-PCR. Padi6 was undetectable in all three cell types. Expression 
normalized to endogenous levels of Ubiquitin (UbC). Error bars represent the 
standard error of the mean of three biological replicates. 
 
(b) Transcript levels of Padi1, Padi2 and Padi3 in ES cells upon switch to 2i 
containing medium for one passage, as assessed by qRT-PCR. Padi6 was 
undetectable in both conditions. Expression normalized to UbC. Error bars represent 
the standard error of the mean of three biological replicates. 
 
(c) Immunoblot analysis of H3Cit levels in ES, NS and iPS cells. Total H3 is 
presented as loading control. 
 
(d) Immunoblot analysis of total citrullination the levels in ES, NS and iPS cells, using 
an antibody against Modified Citrulline (ModCit) which recognizes peptidylcitrulline 
irrespective of amino acid sequence. Total H3 is presented as loading control. 
 
(e) ZHBTc4.1 and 2TS22C ES cell lines were treated with 1µg/ml doxycycline for 48 
hours, resulting in depletion of Oct4 or Sox2 (data not shown). Padi4 mRNA was 
significantly reduced upon Oct4, but not Sox2 knockdown, as assessed by qPCR. 
Error bars represent standard error of the mean of four biological replicates. 
 
(f) ChIP-qPCR for Oct4, Sox2, Klf4, RNA polymerase II (PolII), H3K4me3 and H2A 
on the promoter of Padi4 in mES and NS cells. For each cell condition, the signal is 
presented as fold enrichment over Input and after subtracting background signal from 
the beads. Error bars represent the standard deviation of three technical qPCR 
replicates. 
 
Asterisks denote difference with ES cells (a) or media (b), and 0h time point (e); - not 
significant, * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 by ANOVA (a) or t-test 
(b,e). 
 
 
Extended Data Figure 2: 
 
(a) Validation of selected targets from the PADI4 over-expression microarray dataset 
by qRT-PCR. Expression of Pou5f1, Sox2, Klf4 and c-Myc is not affected by PADI4 
over-expression. Expression normalised to UbC. Error bars presented as standard 
error of the mean of three biological replicates.  
 
(b) Transcript levels of mouse Padi4 and human PADI4 in mES cells after transient 
knock-down with Padi4 or control (Ctrl) shRNA, and over-expression of human 
PADI4 or control vector (pPB CTRL), as assessed by qRT-PCR. Expression 
normalized to UbC. Error bars represent the standard error of the mean of three 
biological replicates. 
  
(c) Transcript levels of mouse Padi4, Tcl1 and Nanog in mES cell clones stably 
expressing Padi4 or control (Ctrl) shRNA, as assessed by qRT-PCR. Expression 
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normalized to UbC. Error bars represent the standard error of the mean of three 
biological replicates. 
 
Asterisks denote difference with Ctrl (a,b,c) and between samples (b); - not 
significant, * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001  by ANOVA (b) or t-test 
(a,c). 
 
 
Extended Data Figure 3: 
 
(a) Representative ChIP-qPCR for H2A on regulatory regions of Tcl1 and Nanog in 
mES, NS and iPS cells (corresponding to Fig. 1h). For each cell condition, the signal 
is presented as fold enrichment over Input and after subtracting background signal 
from the beads. Error bars represent the standard deviation of three technical qPCR 
replicates. 
 
(b) ChIP-qPCR for hPADI4 on regulatory regions of Tcl1, Nanog, Klf2 and Kit, which 
are up-regulated by hPADI4 over-expression, in mES cells stably expressing hPADI4. 
For each cell condition, the signal is presented as fold enrichment over Input and 
after subtracting background signal from the beads. Error bars represent the 
standard deviation of three technical qPCR replicates. 
 
(c) Representative ChIP-qPCR for H3Cit on regulatory regions of Tcl1 and Nanog in 
mES cells stably expressing hPADI4 and treated with 200µM Cl-amidine for 48h. For 
each cell condition, the signal is presented as fold enrichment over Input and after 
subtracting background signal from the beads. Error bars represent the standard 
deviation of three technical qPCR replicates. 
 
 
Extended Data Figure 4: 
 
(a) Heat map of the top 70 genes that showed differential expression after PADI4 
inhibition in ES cells by with 200µM Cl-amidine for 48h, as determined by microarray 
analysis. Displayed values are normalized log intensities, minus the mean 
expression of the gene across the two samples. Hierarchical clustering based on 
correlation. 
 
(b) Validation of selected targets from the above microarray dataset by qRT-PCR. 
Expression normalised to UbC. Error bars presented as standard error of the mean 
of three biological replicates. Asterisks denote difference with Ctrl; - not significant, * 
P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001  by t-test. 
 
(c) Gene Ontology for Biological Process (GOBP) analysis for the most regulated 
gene categories within the microarray dataset of Cl-amidine treatment in mES cells. 
P-value is corrected for multiple testing using Benjamini and Hochberg FDR. 
 
 
 
Extended Data Figure 5: 
 
(a) Scheme of reprogramming of neural stem cells to pluripotent state. NSO4G cells 
were retrovirally transduced with Oct4, Klf4 and c-Myc. After 6 days, partially 
reprogrammed pre-iPS cells arose. For shRNA experiments, pre-iPS cells were 
stably transfected with Ctrl or PADI4 shRNA and then full reprogramming was 
performed in the presence of 2iLIF media for 8 days. For PADI4 enzymatic inhibition, 
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pre-iPS cells were immediately changed to 2iLIF media in the presence of the 
inhibitor Cl-amidine for 8 days. 
 
(b) Quantification of flow cytometry analysis for the assessment of Oct4-GFP 
reporter expression in a reprogramming assay using pre-iPS cells stably expressing 
Padi4 shRNA #4 and Ctrl shRNA. Error bars represent standard error of the mean of 
triplicate samples within a representative from four reprogramming experiments. 
 
(c) Quantification of Oct4-GFP positive colonies in the reprogramming assay where 
pre-iPS cells were Padi4 shRNA #4 versus control (see Fig. 2a), after time-lapse 
image acquisition with Biostation CT. Error bars represent standard error of the mean 
of triplicate samples within a representative reprogramming experiment. Time-lapse 
video in supplementary data online. 
 
(d) Immunoblot analysis of H3Cit in pre-iPS cells treated with 2i, after Padi4 knock-
down (PADI4 shRNA #4) versus control cells (Ctrl shRNA). 2i-containing medium 
was added on day 2. Total histone H3 presented as loading control. 
 
(e) Quantification of flow cytometry analysis for the assessment of Oct4-GFP reporter 
expression in a reprogramming assay using pre-iPS cells stably expressing Padi4 
shRNA #3 and Ctrl shRNA. Error bars represent standard error of the mean of 
triplicate samples. 
 
(f) qRT-PCR analysis for the expression of Tcl, Nanog and Padi4 mRNAs at the end 
of the above reprogramming assay (e). Error bars represent standard error of the 
mean of triplicate samples. 
 
(g) Quantification of flow cytometry analysis for the assessment of Oct4-GFP 
reporter expression in a reprogramming assay were treated with 200µM Cl-amidine. 
Error bars represent standard error of the mean of triplicate samples within a 
representative from three reprogramming experiment. 
 
(h) Quantification of Oct4-GFP positive colonies in the reprogramming assay where 
pre-iPS cells were treated with 200µM Cl-amidine (see Fig. 2c) after time-lapse 
image acquisition with Biostation CT. Error bars represent standard error of the mean 
of triplicate samples within a representative reprogramming experiment. 
 
(i) Immunoblot analysis for the presence of H3Cit at the end of the above 
reprogramming assay (g). Total histone H3 presented as loading control. 
 
Asterisks denote difference with Control; - not significant, * P≤0.05, ** P≤0.01, *** 
P≤0.001, **** P≤0.0001 by t-test 
 
 
Extended Data Figure 6: 
 
(a) Embryos at 2-cell stage were treated with 200µM Cl-amidine and snapshots were 
taken at E3.0, E3.5 and E4.0. 200µM Cl-amidine embryos arrested at 8-cell stage, 
while Control embryos continued development to form blastocysts. Phase contrast 
images are shown. 
 
(b) Embryos at 2-cell stage were treated with 10µM Cl-amidine for 12 hours, fixed 
and stained for H3Cit at the 4-cell stage. Phase contrast, H3Cit (white) and 
HOECHST 33342 (blue) images are shown. Bar represents 20µm.  
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(c) Embryos at E3.5 were treated with 10µM Cl-amidine for 24 hours, fixed and 
stained for H3Cit at E4.5. H3Cit (green) and HOECHST 33342 (blue) images are 
shown. Bar represents 20µm. 
 
(d) Table with quantifications of lineage commitment in E4.5 blastocysts treated with 
10µM Cl-amidine from the 2-cell stage. Asterisks denote difference with Control, 
unpaired t-test, * = p<0.05. n=3 (50 embryos). 
 
(e) Embryos were cultured in medium supplemented with 10µM Cl-amidine from 2-
cell stage and through preimplantation development. E4.5 blastocysts were fixed and 
stained for SOX17 (primitive endoderm marker, red), Cdx2 (trophectoderm marker, 
green) and HOECHST 33342 (blue). Bar represents 20µm. 
 
(f) Time-lapse analysis of distribution of inner and outer cells at the 8 to 16-cell 
transition, upon culturing of embryos with medium containing 10µM Cl-amidine from 
2-cell stage. Error bars represent standard error of the mean. Statistical significance 
was determined by unpaired t-test	   or	   Mann Whitney test upon non-normal 
distribution. Asterisks denote difference with Control; * P≤0.05. 
 
 
 
Extended Data Figure 7: 
 
(a) Embryos at 2-cell stage were treated with 100µM TDFA for 12 hours and fixed 
and stained for H3Cit at 4-cell stage. H3Cit and HOECHST 33342 images are shown. 
 
(b) Table representing the percentage of cells committed to each embryonic lineage 
in E4.5 blastocysts upon treatment of embryos at 2-cell stage with 100µM TDFA. 
Bars represent mean percentage (±SEM). Asterisks denote difference with Control, 
Mann-Whitney test, * = p<0.05. n=3 (60 embryos). 
 
(c) Embryos at 2-cell stage were treated with 100µM TDFA and fixed at embryonic 
day E4.5. Phase contrast, Nanog (green), Sox17 (purple), Cdx2 (red) and HOECHST 
33342 (blue) images are shown. 
 
 
 
Extended Data Figure 8: 
 
(a) Embryos at 2-cell stage were treated with 10nM TSA for 12 hours, and fixed and 
stained for H3K9ac at 4-cell stage. H3K9ac and HOECHST 33342 images are shown. 
 
(b) Table representing the percentage of cells committed to each embryonic lineage 
in E4.5 blastocysts upon treatment of embryos at 2-cell stage with 10nM TSA. Bars 
represent mean percentage (±SEM). Asterisks denote difference with Control, 
unpaired t-test, * = p<0.05. n=2 (32 embryos). 
 
(c) Embryos at 2-cell stage were treated with 10nM TSA and fixed at embryonic day 
E4.5. Phase contrast, Nanog (green), Sox17 (purple), Cdx2 (red) and HOECHST 
33342 (blue) images are shown. 
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Extended Data Figure 9: 
 
(a) Histogram demonstrating the mass accuracies of all fragment ion masses used 
for identifying citrullinated peptides in our HCD MS/MS spectra. >490.000 y- and b-
ion masses are depicted. The average absolute mass accuracy for all of these 
fragment ions is 3.97 ppm. 
 
(b) Scatter plot representing SILAC ratios in ES cells cultured in 13C6 L-Lysine 
(HEAVY) and LIGHT medium separately, to assess extend and quality of SILAC 
labeling. No significant outliers are observed, indicating equal labeling. 
 
(c) Peptide coverage of histone H1 by LC-MS analysis. Detected peptides are 
highlighted in light green and cover >60% of H1. While all arginine residues of 
Histone H1 (highlighted in dark green) were accounted for by the analysis, Arg54 
was the only one found citrullinated. 
 
(d) Fragmentation spectra of the unmodified LysC peptide ERSGVSLAALKK 
surrounding Arginine 54 of H1.2 (unmodified counterpart of citrullinated peptide 
depicted in Fig. 3d). The y and b series indicate fragments at amide bonds of the 
peptide. 
 
(e) Fragment ion table (expected and observed masses for detected y and b ions) for 
the identified H1R54 citrullination of peptide ERSGVSLAALKK on histone H1.2 (as 
shown in Fig. 3d). All measured fragment ions were detected with mass accuracies 
<10ppm, unambiguously identifying that the detected peptide sequence harbors a 
citrullination at position R54. 
 
(f) Theoretical and measured b- and y-ion fragment masses for the corresponding 
unmodified and heavy SILAC labeled H1.2 peptide, as presented in (d) above. 
 
 
Extended Data Figure 10: 
 
(a) MS spectrum of Histone H1.5 in a SILAC proteomic screen for identification of 
PADI4 substrates. Linker histone H1.5 is deiminated by PADI4, as identified by a 
highly increased SILAC ratio of the heavy labeled identified peptide (marked by a red 
dot). 
 
(b) Fragmentation spectra of the doubly charged LysC peptide ERGGVSLPALK 
surrounding Arginine 54 of H1.5. The y and b series indicate fragments at amide 
bonds of the peptide, unambiguously verifying the citrullinated peptide. 
 
 
Extended Data Figure 11: 
 
(a) Mutation of R54 renders histone H1.2 refractory to deimination. Immunoblot 
analysis of recombinant histone H1.2 using an antibody that detects all deimination 
events (ModCit). Wild type and R54-mutant H1.2 were treated with recombinant 
PADI4, in the presence of activating calcium. Only wild-type H1.2 can be deiminated, 
indicating that R54 is the only substrate of PADI4 in H1.2. No-calcium reactions 
presented as negative controls. Total H1.2 presented as loading control. 
 
(b)	  Schematic representation of the position of R54 within the globular domain linker 
histone H1.2.	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Extended Data Figure 12: 
 
(a) Immunoblot analysis of the “Pellet” fraction of C2C12 permeabilised cells treated 
with recombinant PADI4. Presence of H3Cit species indicates PADI4 activity. Total 
H3 is presented as a control for equal use of starting material in the two experimental 
conditions.  
 
(b) Immunofluorescence analysis of C2C12 nuclei after treatment with recombinant 
PADI4. Presence of H3Cit species indicates PADI4 activity. DNA is visualised by 
staining with DAPI. 
 
(c) Fragmentation spectra of the citrullination site R54 on the evicted H1.2 peptide 
ERSGVSLAALK (corresponding to Fig. 4b). The evicted Histone H1 is citrulinated at 
R54.	  
 
(d) Theoretical and measured b- and y-ion fragment masses for the citrullinated H1.2 
peptide (peptide sequence ERSGVSLAALK) evicted after treatment of C2C12 cells 
with recombinant hPADI4 (corresponding to Fig. 4b). 
 
(d) Micrococcal nuclease digestion of C2C12 nuclei after treatment with recombinant 
PADI4, as described in Fig. 4a. M= size marker. 
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Supplementary Methods 
Cell Culture 
NSO4G neural stem cells1 were cultured in RHB-A media (Stem Cell Sciences, 
Cambridge, UK), supplemented with penicillin/streptomycin (Life Technologies) and 
10ng/ml bFGF and EGF (PeproTech). ES Oct4-GIP cells2 and E14 ES cells were 
cultured in GMEM supplemented with 10% fetal calf serum (FCS) for ES cells 
(Biosera), 0.1mM non-essential amino acids, penicillin/streptomycin, 2mM L-
glutamine, 1mM sodium pyruvate, 0.1mM beta-mercaptoethanol and 106 units/L 
leukemia inhibitory factor (LIF) (ESGRO, Millipore), or in 2i/LIF media, based on 
GMEM and containing 10% Knock-Out Serum Replacement (Life Technologies), 1% 
FCS for ES cells (Biosera), 0.1mM non-essential amino acids, 
penicillin/streptomycin, L-glutamine, sodium pyruvate, 0.1mM beta-mercaptoethanol, 
1µM PD0325901 (AxonMedChem, Groningen, The Netherlands), 3µM CHIR99021 
(AxonMedChem, Groningen, The Netherlands) and 106 units/L LIF (ESGRO, 
Millipore). Plat-E packaging cells were grown in DMEM media (Life Technologies) 
supplemented with 10% FCS, 1µg/ml puromycin, 10µg/ml blasticidin and 
penicillin/streptomycin. iPS cells were maintained in 2i/LIF media. 1µg/ml puromycin 
was added to iPS and ES Oct4-GIP cultures during expansion. ZHBTc4.13 and 
2TS22C4 ES cell lines were expanded in ES cell media and treated with 1µg/ml 
doxycycline for 48h prior to RNA extraction and qRT-PCR analysis. Complete knock-
down of Oct4 in the ZHBTc4.1 cell line and of Sox2 in the 2TS22C ES cell line was 
confirmed by western blot (data not shown). All cells were grown at 37°C with 5% 
(Biostation) or 7.5% CO2. 
 
Over-expression of human PADI4 or shRNA against mouse Padi4 in mES cells 
Human PADI4 was inserted in ES E14 cells using the piggyBac transposon system5. 
The Gateway system was used to clone hPADI4 into the piggyBac vector using the 
following primers: 
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PADI4_AttB1_F: 
 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGCCCAGGGGACATTGA
TCCG; 
PADI4_AttB2_R: 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGGGCACCATGTTCCACC. 
1µg PB-CAG-Ctrl or PB-CAG-hPADI4 vectors were transfected with 2µg piggyBac 
transposase (PBase) expression vector, pCAGPBase, by nucleofection according to 
the manufacturers’ instructions (Lonza). ES E14 cells constitutively expressing the 
hygromycin resistance gene and hPADI4 were selected and expanded in media 
containing 200µg/ml hygromycin. 
 
For mouse Padi4 knock-down experiments, ES E14 cells were transfected with 
Lipofectamine 2000 (Life Technologies) or by nucleofection with pRFP-C-RS HuSH 
shRNA RFP vectors (Origene) containing either the scrambled shRNA cassette 
TR30015 (Ctrl), mouse Padi4 targeting shRNAs FI516326 (shRNA#1) or FI516328 
(shRNA#2), or with Mission RNAi pLKO.1-puro vectors (Sigma), containing either the 
non-targeting shRNA SHC002 (Ctrl) or mouse Padi4 targeting shRNA 
TRCN000101833 (shRNA#3). Where applicable ES cell lines were generated after 
selection with 1µg/ml puromycin.  
 
Reprogramming 
Reprogramming was performed as described in Silva et al., 2009 and Theunissen et 
al, 20116,7. For retroviral supernatant preparation, 9 µg of pMXs-Oct4, pMX-Klf4 and 
pMXs-c-Myc were transfected FuGENE 6 into 1-2x106 Plat-E cells in separate 10cm 
dishes. After 24h incubation, the media was replaced with DMEM+10% FCS and 
penicillin/streptomycin. Virus-containing supernatants from Plat-E cultures were 
filtered through a 0.22-µm cellulose acetate filter, mixed in equal ratios, and 4µg/ml 
polybrene was added. 2 mls of the final viral mix was then added to previously plated 
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1.2x105 NSO4G cells, in 6-well plates coated with gelatin. After 1 day, the media was 
replaced with NS cell culture medium. After 3 days incubation, the media was 
changed to ES cell serum-containing media (see above). At this stage, pre-iPS 
colony formation was evident, but none of the colonies was positive for GFP 
expression (GFP+). After 2 days and to complete reprogramming, medium was 
replaced with 2i/LIF. Cells were maintained in 2i/LIF for 8 days, with media change 
every 2 days. Oct4-GFP+ colonies were counted at day 7 in 5-9 selected fields per 
well, either at the microscope or after time-lapse image acquisition on the Biostation 
CT (Nikon, Japan). The percentage of GFP+ cells was determined by flow cytometry 
at day 8, using a Dako Cytomation CyAN ADP high-performance cytometer and 
Summit software, as described in Silva et al., 2009 and Theunissen et al, 20116,7. 
Statistical significance was determined by two-tailed unpaired t-test. For the time 
course experiments, cells were collected with 350µl RLT buffer (Qiagen) or 2X 
Laemmli buffer, from individual wells in consecutive days and after a PBS wash. 
 
200µM Cl-amidine was added at the time of media exchange to 2i/LIF and 
replenished every 2 days. For Padi4 knock-down experiments, pre-iPS cells were 
maintained in ES cell serum-containing media and cell lines were generated after 
transfection with lipofectamine 2000 with the Mission RNAi pLKO.1-puro vectors, 
containing either a non targeting shRNA (SHC002) or mouse Padi4 targeting 
shRNAs TRCN000101833 (shRNA#3) or TRCN000101834 (shRNA#4). Following 
puromycin selection, control and Padi4 knock-down pre-iPS cell lines were 
generated. Importantly, puromycin treatment abolished all non-transfected pre-iPS 
cells and Ctrl and shPadi4 pre-iPS cell lines were Oct4-GFP negative (Fig. 2A). For 
reprogramming experiments, 1x105 cells were plated in individual wells  (6-well 
plates) in triplicate and without puromycin, and media was changed to 2i/LIF after 
day 1. Cells were maintained in 2i/LIF for 8 days, with media change every 2 days, 
and assessed for Oct4-GFP as previously described.  
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qRT-PCR 
Primer design Genbank and Ensembl cDNA sequences were used to design gene 
specific primers in Primer 38 or in the Universal ProbeLibrary Assay Design Center 
(Roche Applied Science). The specificity of PCR primers was determined via the in-
Silico PCR (UCSC Genome Browser) and Primer-BLAST (NCBI) web-based tools.  
Oligonucleotides were obtained from Sigma. Primer sequences can be found in 
Supplementary Table 1. 
Reverse Transcription Total RNA was isolated from ES cells, NSO4G and cells 
during reprogramming, using the RNeasy extraction kit with in-column DNAse 
treatment (Qiagen). Total RNA was reverse transcribed with the High-Capacity cDNA 
Reverse Transcription Kit for 1 hour (Applied Biosystems). Samples were aliquoted 
equally into positive and negative (RT-) reactions. Prior to qPCR analysis, samples 
were diluted 5- or 10-fold with DNAse/RNAse free dH2O (Ambion). 
qPCR qPCR reactions were performed in duplicate or triplicate for each sample. 
Each PCR reaction had a final volume of 10-20µl and 2.5-5µl of diluted cDNA or 
ChIP DNA. RT- samples were assayed to discount genomic DNA amplification. Fast 
SYBR Green Master Mix or TaqMan Fast Universal PCR Master Mix (Applied 
Biosystems) were used, according to the manufacture’s instructions. A melting curve 
was obtained for each PCR product after each run, in order to confirm that the SYBR 
Green signal corresponded to a unique and specific amplicon. Random PCR 
products were also run in a 2-3% agarose gel to verify the size of the amplicon. 
Standard curves were generated for each real-time PCR run using serial 3-fold 
dilutions of a sample containing the sequence of interest. Their plots were used to 
convert CTs (number of PCR cycles needed for a given template to be amplified to 
an established fluorescence threshold) into arbitrary quantities of initial template per 
sample. Expression levels were then obtained by dividing the quantity by the value of 
housekeeping genes, such as ubiquitin (UbC). UbC assays were run every time 
samples were frozen/thawed. Statistical analysis was performed in Prism 6 using 
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one-way ANOVA analysis of variance with Holm-Sidak's multiple comparisons test or 
two-tailed unpaired t-test. 
 
Gene expression analysis 
Mouse WG-6 Expression BeadChip microarrays (Illumina) were processed at the 
Cambridge Genomic Services, Department of Pathology, University of Cambridge. 
Three biological replicates were assayed for each condition. Illumina microarray 
probes were matched to gene identifiers according to the re-annotation of the 
microarray platform9. For both the Padi4 overexpression and the Cl-amidine inhibition 
experiments, normalization was performed using the lumi10 R package. Limma11  was 
used for differential expression analysis, with Benjamini-Hochberg (FDR) adjusted p-
values <0.05 considered significant. Gene ontology (GO) enrichment analysis was 
performed using GOstats12, and results adjusted for multiple testing using the 
Benjamini-Hochberg procedure (FDR).  
 
Immunoblot analysis 
For immunoblot analysis, cell monolayers or pellets were resuspended in 2X 
Laemmli buffer, incubated for 5 mins at 95°C and passed 10 times through a 21G 
needle to shear genomic DNA. In the case of Trichloroacetic acid precipitated 
proteins, pellets were resuspended in buffer and boiled as above. Proteins were 
separated by SDS–PAGE, transferred to nitrocellulose membrane (Millipore) using 
wet transfer and incubated in blocking solution (5% BSA in TBS containing 0.1% 
Tween) for 1h at room temperature. Membranes were incubated with primary 
antibody at 4oC overnight and appropriate HRP-conjugated secondary antibody for 
2h at room temperature. Membranes were then incubated for enhanced 
chemiluminescence (ECLH; GE Healthcare) and proteins were detected by exposure 
to X-ray film. Primary antibodies, diluted in blocking solution were used against 
citrullinated histone H3 (α-H3Cit, Abcam, ab5103 at 1:50,000 dilution), unmodified 
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histone H3 (α-H3, Abcam, ab10799 at 1:2,000), linker histone H1 (α-H1, Santa Cruz 
Biotechnology, sc-34464 at 1:200), GFP (α-GFP, Abcam, ab290 at 1:5000) and 
Gapdh (α-Gapdh, Abcam, ab9485 at 1:2500). Citrulline-containing proteins were 
modified on the membrane and detected using Anti-Modified Citrulline detection kit 
(Millipore) as per manufacturer’s instructions.  
 
Chromatin immunoprecipitation  
ChIP-IT Express (Active Motif) was used according to the supplier’s 
recommendations. Cells were cross-linked using 1% formaldehyde for 10 min at 
room temperature.  Formaldehyde was quenched by a 5-minute incubation with 
glycine, cells were rinsed twice with cold PBS, collected by scraping and pelleted at 
2500 rpms for 10 minutes at 4°C. Frozen pelleted cells were thawed and 
resuspended in lysis buffer, rotated for 30 minutes at 4°C, dounced and centrifuged 
at 5000 rpms for 10 mins at 4°C. Pelleted nuclei were resuspended in shearing 
buffer. Chromatin was then sonicated using a Bioruptor™ 200 (Diagenode), high 
frequency, 0.5 min/0.5min, for 10 minutes twice. Sonicated chromatin was analysed 
in 1% agarose gel, to confirm efficient sonication. Input was collected for further 
analysis. 5-15 µg of chromatin was incubated with 2µg of rabbit IgG as control 
(Abcam, ab6742), α-PADI4 (Sigma, P4749), α-Klf4 (R&D Systems, AF3158), α-Oct4 
(Santa Cruz Biotechnology, sc-5279X (mouse) or sc-8628X (goat)), α-Sox2 (Santa 
Cruz Biotechnology, sc-17320), α-H3Cit (Abcam, ab5103), α-H2A (Abcam, 
ab18255), α-H3K4me3 (Millipore, #17-614), α-RNA polymerase II (Millipore, clone 
CTD4H8, #05-623) or α-H1.2 (a-H1C, a kind gift from Prof. Arthur Skoultchi, Albert 
Einstein School of Medicine) for 1 hour at 4°C and subsequently with protein G 
magnetic beads. After overnight immunoprecipitation at 4°C, beads were washed 3 
times with ChIP buffer 1 and 2 times with ChIP buffer 2. After elution and reverse 
cross-link (95°C for 15 minutes), samples were treated with proteinase K for 1 hour. 
Purified DNA and 1% input were analysed by Fast SYBR Green Master Mix qPCR, 
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using serial 4-fold dilutions of the concentrated input for standard curves and 
triplicates per sample. Occupancy is plotted as fold enrichment over input and after 
subtracting background signal from the beads. Primers are listed in Supplementary 
Table 1. 
 
Embryo Collection and Culture 
Embryos were collected into M2 medium (incl. 4 mg/ml BSA) from superovulated 
C57Bl6xCBA females mated with C57Bl6xCBA or H2B-EGFP13 males as previously 
described14. Embryos were cultured in KSOM (incl. 4 mg/ml BSA) under paraffin oil in 
5% CO2 at 37.5°C. PADI4 inhibitors (Cl-amidine, 10µM or 200µM, and TDFA, 
100µM) and HDAC inhibitor (TSA, Sigma, 10nM) were added to final KSOM from 2-
cell stage embryos (44 h after hCG) onwards. The concentration for inhibitors was 
determined by titration, and was set as the lowest dose that leads to inhibition of 
enzyme activity and allowed embryonic development to blastocyst stage.  Animals 
were maintained in the Animal Facility of the Gurdon Institute at a 12:12 light cycle 
and provided with food and water ad libitum. All experiments were conducted in 
compliance with Home Office regulations. 
 
Immunofluorescence Staining and Analysis of Embryos 
Embryos were fixed in 4% PFA for Nanog, Sox17, Cdx2 and H3K9 acetylated 
staining, and in methanol for H3Cit staining. Immunofluorescence staining was 
carried out as described by Jedrusik et al, 200815. Primary antibodies used were as 
follows: rabbit α-H3Cit (Abcam, 1:100), rabbit α–H3K9ac (Upstate, 1:100), rabbit α-
Nanog (Cosmo Bio Co., 1:200), goat α-Sox17 (R&D systems, 1:200), mouse α-Cdx2 
(Cdx2-88) (Biogenex, 1:200). Secondary antibodies used were AlexaFluor 568-
conjugated donkey anti-goat, AlexaFluor 488–conjugated donkey anti-mouse and 
AlexaFluor 633–conjugated donkey anti-rabbit, and AlexaFluor 488-conjugated anti-
rabbit and Texas Red-conjugated goat anti-rabbit (Invitrogen, Carlsbad, CA), at 
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1:400. Collection of 4- cell embryos and E4.5 blastocysts was performed 56 h and 
106 h after hCG, respectively. Confocal microscopy was performed and images 
analyzed using a 40/1.4 NA oil DIC Plan-Apochromatic lens on an inverted Zeiss 510 
Meta confocal microscope (Thornwood, NY). Confocal sections were taken every 2 
µm through the whole embryo. To objectively measure the fluorescence levels of 
H3Cit, individual cells were outlined manually in Image J, and the intensity of the 
fluorescent signal was recorded for each z-stack (3 measurements per nucleus). 
Only cells in the same z-stacks were compared. Statistical analysis was performed 
with two-tailed unpaired t-test or Mann Whittney test (for non-normal distributions). 
Fluorescence and DIC Z-stacks of embryos from late 2-cell (52 h after hCG) to 
blastocyst stage were collected on 15 focal planes every 15 min for 72 h of 
continuous embryo culture. The images were processed as described by Bischoff et 
al., 2008. All cells were followed in 4D using SIMI Biocell software 
(http://www.simi.com/en/products/biocell/index.html/)16 as previously described 
(Bischoff et al., 2008)14.  
 
SILAC labeling and Mass Spectrometry 
ES cells were labeled in culture using the Mouse Embryonic Stem Cell SILAC 
Protein Quantitation Kit (Pierce) for at least 6 passages. Extracted proteins were 
resuspended in Laemmli sample buffer, and resolved on a 4-20% SDS-PAGE 
(NuPAGE, Life Technologies). The gel was stained with Coomassie Blue, cut into 20 
slices and processed for mass spectrometric analysis using standard in gel 
procedure17. Briefly, cysteines were reduced with dithiothreitol (DTT), alkylated using 
chloroacetamide (CAA),18 and finally the proteins were digested overnight with 
endoproteinase Lys-C and loaded onto C18 StageTips prior to mass spectrometric 
analysis. 
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All MS experiments were performed on a nanoscale HPLC system (EASY-nLC from 
Thermo Scientific) connected to a hybrid LTQ–Orbitrap Velos19 equipped with a 
nanoelectrospray source (Thermo Scientific). Each peptide sample was auto-
sampled and separated on a 15 cm analytical column (75cm inner diameter) in-
house packed with 3- m C18 beads (Reprosil Pur-AQ, Dr. Maisch) with a 2h gradient 
from 5% to 40% acetonitrile in 0.5% acetic acid. The effluent from the HPLC was 
directly electrosprayed into the mass spectrometer. 
 
The MS instrument was operated in data-dependent mode to automatically switch 
between full-scan MS and MS/MS acquisition. Survey full-scan MS spectra (from m/z 
300–1,700) were acquired in the Orbitrap mass analyser with resolution R = 30,000 
at m/z 400 (after accumulation to a 'target value' of 1,000,000 in the linear ion trap). 
The ten most intense peptide ions with charge states ≥2 were subsequently isolated 
to a target value of 50,000 using predictive automatic gain control (pAGC) and 
fragmented by higher-energy collisional dissociation (HCD) in the octopole collision 
cell using normalized collision energy of 40%. The ion selection threshold was set to 
5,000 counts for HCD and the maximum allowed ion accumulation times was set to 
500 ms for full scans and 250 ms for HCD. All HCD fragment ion spectra were 
recorded in the Orbitrap mass analyzer with a resolution of 7,500 at m/z 400. For all 
full scan measurements a lock-mass ion from ambient air (m/z 445.120025) was 
used for internal calibration when present, as described20.  
 
Identification of peptides and proteins  
Mass spectrometry data analysis was performed with the MaxQuant software suite 
(version 1.2.6.20) as described21 supported by Andromeda (www.maxquant.org) as 
the database search engine for peptide identifications22. We followed the step-by-
step protocol of the MaxQuant software suite23 to generate MS/MS peak lists that 
were filtered to contain at most six peaks per 100 Da interval and searched by 
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Andromeda against a concatenated target/decoy24 (forward and reversed) version of 
the Uniprot human database version (70.101 forward protein entries). Protein 
sequences of common contaminants such as human keratins and proteases used 
were added to the database. The initial mass tolerance in MS mode was set to 7 
ppm and MS/MS mass tolerance was set to 20 ppm. Cysteine carbamidomethylation 
was searched as a fixed modification, whereas protein N-acetylation, oxidized 
methionine, deamidation of Asparagine and Glutamine, and citrullination of Arginines 
were searched as variable modifications. A maximum of two miscleavages was 
allowed while we required strict LysC specificity. Peptide assignments were 
statistically evaluated in a Bayesian model on the basis of sequence length and 
Andromeda score. We only accepted peptides and proteins with a false discovery 
rate of less than 1%, estimated on the basis of the number of accepted reverse hits. 
 
Native purification of wild-type and mutant linker histone H1.2 
Linker histone H1.2 was expressed from a pET 28b(+) vector, kindly provided by the 
laboratory of Robert Schneider (MPI fuer Immunobiologie, Freiburg). The vector was 
mutated using Quickchange® site-directed mutagenesis protocol (Stratagene) for the 
expression of R54A and R54K mutants. After transformation into expression strain 
BL21(DE3)-RIL, pre-cultures were diluted 1:100 into 3L  of LBKan/Cam medium at 37oC, 
200rpm. At OD600 of 0.6, 0.2mM IPTG was added and the bacteria grown for another 
2h under the same conditions. Bacterial pellets were harvested by centrifugation (15 
min, 4,000xg, 4oC), frozen in liquid nitrogen and stored at -80oC. Linker histone 
expression was assessed by SDS-PAGE and Coommassie Blue stain. Pellets were 
thawed on ice, resuspended in 25 mL lysis buffer [20mM hepes, pH 7.6; 100mM 
NaCl; 5mM EDTA; 1X complete protease inhibitors (Roche); 1mM DTT; 0.2mM 
PMSF] per litre of culture and lysed through an Avestin high-pressure homogenizer. 
Lysates were cleared by centrigugation (20,000xg, 40 min, 4oC) and 4M ammonium 
sulfate added slowly to the supernatant to a final concentration of 2M. The mixture 
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was incubated on an end-to-end rotator at 4oC for 20 mins before the precipitated 
proteins were removed by centrifugation (20,000xg, 40 min, 4oC). The supernatant 
was filtered through a 0.2µm syringe filter and loaded onto a 20 mL HiPrep 16/10 
Phenyl FF (low sub) hydrophobic interaction column (Amersham Biosciences), 
equilibrated in HEMG buffer [20 mM Hepes, pH 7.6; 50µM EDTA; 6.25 mM MgCl2; 
0.5 mM DTT; 10% glycerol] containing 2M ammonium sulfate. The sample was 
injected via a 50 mL super loop at a flow rate of 0.5 ml/min, while the flow through, 
which contained H1.2, was collected in 5 mL fractions. Ten column volumes of 
HEMG buffer were used to flush the remaining H1.2 from the column. Fractions were 
analysed by SDS-PAGE and H1.2-containing fractions were pooled and dialyzed 
overnight into HEG buffer [20 mM Hepes, pH 7.6; 50µM EDTA; 10% glycerol] 
containing 100 mM NaCl, using 6-8 kDa MWCO dialysis tubing. The protein solution 
was centrifuged (20,000 × g, 40 min, 4oC) to remove precipitated proteins and filtered 
as above. The solution was loaded onto a 6 mL Resource S column, pre-equilibrated 
with HEG buffer, and proteins eluted with a gradient of 100 mM to 1M NaCl-
containing HEG buffer (0.5 mL/mig, 20CV) in 500 µL fractions. Protein fractions were 
analysed and pooled for the presence of H1.2 as above and dialyzed in HEG buffer 
with 100 mM NaCl using dialysis tubing with 10 kDa MWCO. Samples were filtered 
as above and loaded onto a Mono S column (Amersham Biosciences) equilibrated 
with HEG buffer containing 100 mL NaCl. 500 µL fractions were collected with a 
gradient of 100 mM to 1M NaCl-containing HEG buffer (0.5 mL/mig, 20CV) and 
analysed on a 15% SDS-PAGE. Fractions containing H1.2 were pooled, dialyzed as 
above into 50% glycerol and stored at -20oC.  
 
H1.GFP and Nucleosome pull-down assays 
GFP-tagged linker histone H1.2 (H1.GFP) was expressed in ES cells stably over-
expression hPADI4 or control vector by transfection (Lipofectamine 2000) of a 
pEGFP-H1.2 vector, containing either the wild-type or the R54A mutant sequence, or 
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with empty pEGFP vector. Transfection efficiency was assessed by visualization of 
GFP using fluorescence microscopy and determined to be >90%. 24h after 
transfection cells were harvested and H1.GFP was pulled down using GFP-TRAP 
conjugated magnetic beads (Chromotek) as per manufacturer’s instructions, and 
subjected to immunoblot analysis.  
 
For in vitro nucleosome pull-downs, nucleosomes containing purified and refolded 
histone octamers and biotinylated 601 DNA were assembled as described 
previously25 and immobilized on Dynabeads Streptavidin MyOne T1 (Invitrogen) for 
2h at 4oC. Nucleosome-loaded beads in varying amounts were incubated on an end-
to-end rotator with wild-type or mutant linker histone H1.2 in Binding buffer [20 mM 
HEPES, pH 7.9; 150 mM NaCl; 0.2 mM EDTA, 20% Glycerol; 0.1% NP40; 1 mM 
DTT, and complete protease inhibitors (Roche)] for 4 hr at 4oC. After five washes in 
binding buffer, the beads were collected and bound proteins were eluted in sample 
buffer and subjected to Immunoblot analysis.  
 
Purification of recombinant PADI4.GST and in vitro deimination assays 
Recombinant human PADI4.GST was expressed from pGEX6p constructs in LBKan 
media, induced with 0.1 mM IPTG at 25oC, purified using glutathione-sepharose 
resin, eluted using a 25mM glutathione solution and stored in 50% glycerol at -20oC. 
In vitro deimination of linker histone H1.2 was carried out in deimination buffer [50 
mM HEPES, pH 7.5; 2 mM DTT; in the presence of absence of 10 mM CaCl2] at 
37oC for 1h, using the active enzyme. Samples were resuspended in sample buffer 
for immunoblot analysis.  
 
Treatment of permeabilized cells with recombinant PADI4  
Cells were resuspended in a cold solution of 80µg/ml digitonin in SuNaSP26, mixed 
gently but thoroughly and incubated on ice for 3mins. Complete permeabilization was 
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checked by Trypan Blue uptake of sub-aliquots of the suspension and the reaction 
was stopped by addition of SuNaSP containing 3% BSA. Permeabilized cells were 
then pre-incubated in wash buffer [20mM Hepes-KOH, 75mM KCl, 1.5mM MgCl2, 
5mM CaCl2] with 0.2% Triton X-100 for 30mins at 37°C. Nuclei are washed in wash 
buffer and incubated in reaction buffer [20mM HEPES-KOH, 75mM KCl, 1.5mM 
MgCl2, 5mM CaCl2, 2mM DTT] with or without recombinant PADI4 for 1.5hrs at 37°C. 
The nuclei were washed several times in wash buffer to remove excess PADI4 and 
released proteins that were not stably bound within the nucleus. The "Washes" 
fraction contains all proteins that are no longer stably bound, including recombinant 
hPADI4. The "Pellet" contains all other nuclear-retained proteins. The wash 
supernatants were concentrated by trichloroacetic acid protein precipitation and 
subjected to Immunoblot analysis. The washed nuclei were washed a further time in 
PBS for immunoblot analysis or in MNase buffer and used for DNA compaction 
assays.  
 
Micrococcal nuclease digestion 
Cell pellets were washed twice and resuspended in Micrococcal nuclease (MNase) 
buffer [15mM Tris, pH 7.5; 15mM NaCl; 60mM KCl; 0.34M sucrose; 0.5mM 
spermidine; 0.15mM spermine; 0.25mM PMSF; 0.1% β-mercaptoethanol]. 1mM of 
CaCl2 was added and the suspension was divided into equal aliquots, which were 
kept on ice. MNase was added to a final concentration of 0.5U/mL and samples were 
incubated at 25oC in a heat block for varying amounts of time. The reaction was 
stopped by addition of 0.5M EDTA and 0.5M EGTA and DNA purified using a 
QIAGEN® PCR purification kit. DNA was quantified and 1500ng of each sample were 
loaded on a 1.5% agarose gel containing ethidium bromide.  
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